Next Article in Journal
A New Cytotoxicity Assay for Brevetoxins Using Fluorescence Microscopy
Previous Article in Journal
An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIα and Potent Anticancer Agent
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2014, 12(9), 4851-4867; https://doi.org/10.3390/md12094851

Purification of a Low Molecular Weight Fucoidan for SPECT Molecular Imaging of Myocardial Infarction

1
Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France
2
Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
3
Multimodal Imaging Research Federation (FRIM), Paris Diderot University, F-75877, Paris, France
4
Nuclear Medicine Department, Bichat-Claude Bernard Hospital, AP-HP, F-75877, Paris, France
5
Laboratory CSPBAT, Paris 13 University, Sorbonne Paris Cité, CNRS UMR 7244, SBMB team, F-93017, Bobigny, France
6
Laboratory of Polymers Biopolymers Surfaces, Normandie University, Rouen University, F-76821, Mont Saint Aignan, France
7
Laboratory of Polymers Biopolymers Surfaces, CNRS, UMR 6270 and FR3038, F-76821, Mont Saint Aignan, France
8
Algues & Mer, Kernigou, F-29242, Ouessant, France
*
Author to whom correspondence should be addressed.
Received: 31 July 2014 / Revised: 5 September 2014 / Accepted: 9 September 2014 / Published: 23 September 2014
View Full-Text   |   Download PDF [718 KB, uploaded 24 February 2015]   |  

Abstract

Fucoidans constitute a large family of sulfated polysaccharides with several biochemical properties. A commercial fucoidan from brown algae, containing low molecular weight polysaccharidic species constituted of l-fucose, uronic acids and sulfate groups, was simply treated here with calcium acetate solution. This treatment led to a purified fraction with a yield of 45%. The physicochemical characterizations of the purified fucoidan using colorimetric assay, MALLS, dRI, FT-IR, NMR, exhibited molecular weight distributions and chemical profiles similar for both fucoidans whereas the sulfate and l-fucose contents increased by 16% and 71%, respectively. The biodistribution study in rat of both compounds labeled with 99mTc evidenced a predominant renal elimination of the purified fucoidan, but the crude fucoidan was mainly retained in liver and spleen. In rat myocardial ischemia-reperfusion, we then demonstrated the better efficiency of the purified fucoidan. This purified sulfated polysaccharide appears promising for the development of molecular imaging in acute coronary syndrome. View Full-Text
Keywords: fucoidan; molecular imaging; atherothrombosis; SPECT fucoidan; molecular imaging; atherothrombosis; SPECT
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Saboural, P.; Chaubet, F.; Rouzet, F.; Al-Shoukr, F.; Azzouna, R.B.; Bouchemal, N.; Picton, L.; Louedec, L.; Maire, M.; Rolland, L.; Potier, G.; Guludec, D.L.; Letourneur, D.; Chauvierre, C. Purification of a Low Molecular Weight Fucoidan for SPECT Molecular Imaging of Myocardial Infarction. Mar. Drugs 2014, 12, 4851-4867.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top